Evidence map›Paper›PMID 19648511›Full record

ArticleJournal of the National Cancer Institute2009

Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study.

Caroline Laverdière, Qi Liu, Yutaka Yasui, Paul C Nathan, James G Gurney, Marilyn Stovall, Lisa R Diller, Nai-Kong Cheung, Suzanne Wolden, Leslie L Robison and 1 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 3 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Platinum-induced hearing loss after treatment for childhood cancer.The Cochrane database of systematic reviews · 2016
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015
    Trial
  8. Trial
  9. Article
  10. Diagnosis and management of neuroblastoma in children.World journal of pediatric surgery · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Caroline LaverdièreDepartment of Pediatrics, University of Montreal, Montreal, QC, Canada. caroline.laverdiere@umontreal.ca
Qi Liu
Yutaka Yasui
Paul C Nathan
James G Gurney
Marilyn Stovall
Lisa R Diller
Nai-Kong Cheung
Suzanne Wolden
Leslie L Robison
Charles A Sklar
Memorial Sloan Kettering Cancer Center · USUniversity of Alberta · CADana-Farber Cancer Institute · USRadiation Oncology Associates · USSt. Jude Children's Research Hospital · USUniversité de Montréal · CAUniversity of Michigan–Ann Arbor · USUniversity of Toronto · CA

Funding

Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
NCI NIH HHS U24 CA055727NCI NIH HHS U24 CA55727
6 · The paper itself

Abstract

backgroundThe 5-year survival rate for individuals with neuroblastoma is approaching 70%. Few data exist, however, on the long-term outcomes of these patients, who are often treated at a very young age.

methodsOutcome data were obtained for 954 5-year neuroblastoma survivors who were diagnosed in 1970-1986 and enrolled in the Childhood Cancer Survivor Study (CCSS). Late mortality, second malignant neoplasms, and chronic health conditions were analyzed in relation to treatment factors using Poisson regression models and their modification with generalized estimating equations. Neuroblastoma survivors were compared with a cohort of 3899 siblings of CCSS participants for risk of chronic health conditions and selected sociodemographic outcomes. All statistical tests were two-sided.

resultsSix percent of patients died more than 5 years after their diagnosis (standardized mortality ratio = 5.6; 95% confidence interval [CI] = 4.4 to 6.9). The most common causes of death were disease recurrence (n = 43) and second malignant neoplasms (n = 13). The cumulative incidence of second malignant neoplasms was 3.5% at 25 years and 7.0% at 30 years after diagnosis. Compared with the sibling cohort, survivors had an increased risk of selected chronic health conditions (risk ratio [RR] = 8.3; 95% CI = 7.1 to 9.7) with a 20-year cumulative incidence of 41.1%. The most prevalent outcomes involved the neurological, sensory, endocrine, and musculoskeletal systems, with 20-year cumulative incidences of 29.8%, 8.6%, 8.3%, and 7.8%, respectively. Neuroblastoma survivors who were treated with multimodality therapy were more likely to develop a chronic health condition than survivors treated with surgery alone (RR = 2.2; 95% CI = 1.6 to 3.0). Neuroblastoma survivors were less likely than siblings to have ever been employed (P = .04) or to be married (P < .001) and had a lower personal income (P = .009).

conclusionsNeuroblastoma survivors have an increased rate of mortality and second malignant neoplasms, relative to the age- and sex-comparable US population, and of chronic health conditions, relative to their siblings, which underscores the need for long-term medical surveillance.

Indexed as

AdolescentAdultCanadaChildChronic DiseaseFemaleHealth StatusHumansIncidenceMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryNeuroblastomaOdds RatioQuality of Life

Identifiers

PMID19648511
PMCPMC2728747
OpenAlexW2126177906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.